Tuesday, 13.9.2011
8.00-10.00 Main Hall (Aula Duza)
Oral presentations 6: Graves’ Disease (OP39-OP46)
Chair: Matthias Schott (Düsseldorf, Germany); Marcin Barczynski (Krakow, Poland)
OP39 A NOVEL MECHANISM INVOLVED IN THE PATHOGENESIS OF GRAVES OPHTHALMOPATHY (GO) - CLATHRIN IS A POSSIBLE TARGETING MOLECULE FOR INHIBITING LOCAL IMMUNE RESPONSE IN THE ORBIT
Meyer zu Hörste M1,2, Ströher E1, Schmitz-Spanke S3, Pink M3, Göthert J4, Fischer J5, Gulbins E2, Eckstein A1
1University Hospital Essen, Department of Ophthalmology, Essen, Germany, 2University Hospital Essen, Department of Molecular Biology, Essen, Germany, 3University Hospital Essen, Department of Hygiene and Occupational Medicine, Essen, Germany, 4University Hospital Essen, Department of Hematology, Essen, Germany, 5University Hospital Essen, Department of Pharmacology, Essen, Germany
OP40 THE ECONOMIC BURDEN OF GRAVES´ ORBITOPATHY
Ponto KA1, Hommel G2, Pitz S1, Pfeiffer N1, Kahaly GJ1
1University Medical Center, Ophthalmology, Mainz, Germany, 2University Medical Center, Medical Statistics, Mainz, Germany
OP41 SERUM BAFF CONCENTRATIONS IN PATIENTS WITH GRAVES' DISEASE (GD) AND ORBITOPATHY (GO) BEFORE AND AFTER IMMUNOSUPPRESSIVE TREATMENT
Vannucchi G1, Covelli D1, Currò N2, Maffini A1, Dazzi D3, Bonara P4, Pignataro L5, Beck-Peccoz P1, Salvi M1
1Endocrine Unit, Fondazione Cà Granda IRCCS, Milan, Italy, 2Ophthalmology, Fondazione Cà Granda, IRCCS, Milan, Italy, 3Division of Internal Medicine, Fidenza, Italy, 4Internal Medicine, Fondazione Cà Granda IRCCS, Milan, Italy, 5Otolaryngology, Fondazione Cà Granda IRCCS, Milan, Italy
OP42 CIRCULATING CXCL10 AND CCL2 CHEMOKINES IN PATIENTS WITH GRAVES' OPHTHALMOPATHY WITH PREVALENT EXTRAOCULAR MUSCLE INVOLVEMENT: MODULATION BY CYTOKINES AND BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS IN PRIMARY MYOBLASTS
Ferrari SM1, Fallahi P1, Sellari Franceschini S2, Ferrannini E1, Minuto M3, Mancusi C1, Ruffilli I1, Antonelli A1
1University of Pisa, Department of Internal Medicine, Pisa, Italy, 2University of Pisa, Otorhinolaryngology Unit, Pisa, Italy, 3University of Pisa, Department of Surgery, Pisa, Italy
OP43 SERUM SELENIUM IS LOW IN NEWLY DIAGNOSED GRAVES`DISEASE AND AUTOIMMUNE HYPOTHYROIDISM. A POPULATION BASED STUDY
Bülow Pedersen I1, Knudsen N2, Carlé A3, Schomburg L4, Köhrle J4, Jørgensen T5, Perrild H2, Rasmussen L6, Ovesen L7, Laurberg P3
1Aalborg Hospital. Aarhus University Hospital, Dept. of Endocrinology and Medicine, Aalborg, Denmark, 2Bispebjerg Hospital, Copenhagen, Denmark, 3Aalborg Hospital. Aarhus University Hospital, Aalborg, Denmark, 4Institute for Experimental Endocrinology, Berlin, Germany, 5Research Centre for Prevention and Health, Glostrup, Denmark, 6National Food Institute, Copenhagen, Denmark, 7Slagelse Hospital, Slagelse, Denmark
OP44 HYPERTHYROIDISM, RATHER THAN AUTOIMMUNITY, SEEMS TO DETERMINE QUALITY OF LIFE IN PATIENTS WITH GRAVES´ DISEASE
Watt T1,2, Hegedüs L3, Bonnema SJ3, Groenvold M2, Bjorner JB4, Rasmussen ÅK1, Feldt-Rasmussen U1
1Copenhagen University Hospital Rigshospitalet, Dpt. of Medical Endocrinology, Copenhagen, Denmark, 2University of Copenhagen, Health Service Research, Copenhagen, Denmark, 3Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark, 4National Research Center for the Working Environment, Copenhagen, Denmark
OP45 COMPARISON OF EARLY TOTAL THYROIDECTOMY WITH ANTITHYROID TREATMENT IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE GRAVES' ORBITOPATHY, A RANDOMIZED PROSPECTIVE TRIAL
Erdoğan MF1, Demir Ö1, Ersoy RÜ2, Gül K3, Ünlütürk U1, Üç ZA4, Mete T5, Anıl C6, Ertek S7, Çakır B2, Aral Y4, Güler S5, Gürsoy A8, Erdoğan G7, Ankara Thyroid Study Group
1Ankara University Faculty of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, 2Ankara Ataturk Education and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, 3Kahramanmaraş Sütçü İmam University Faculty of Medicine, Endocrinology and Metabolic Diseases, Kahramanmaraş, Turkey, 4Ankara Education and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, 5Ankara Numune Education and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, 6Başkent University Faculty of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, 7Ufuk University Faculty of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, 8Güven Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey
OP46 IS THE ASSOCIATION BETWEEN OVERT HYPERTHYROIDISM AND MORTALITY CAUSAL? CRITICAL REVIEW AND META-ANALYSIS
Brandt F1, Green A2, Hegedüs L1, Brix T1
1Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark, 2Odense University Hospital, Research Unit of Clinical Epidemiology, University of Southern Denmark and Center for National Clinical Databases, South, Odense, Denmark
8.00‐10.00 Minor Hall
Oral presentations 7: Thyroid Cancer (B) (OP47-OP54)
Chair: Georg Brabant (Lübeck, Germany); Beata Kos-Kudla (Katowice, Poland)
OP47 THE TARGETED INACTIVATION OF THE TRβ GENE INCREASES RET-PTC3 - INDUCED GROWTH AND NEOPLASTIC TRANSFORMATION OF THE THYROID GLAND
Selmi-Ruby S1, D'orazio T1, Borson-Chazot F1, Rousset B1
1Centre de Recherche en Cancérologie de Lyon, UMR Inserm 1052 CNRS 5286, Lyon, France
OP48 TRANSCRIPTOME PROFILING OF LASER-MICRODISSECTED PAPILLARY THYROID CANCER CELLS
Oczko-Wojciechowska M1, Swierniak M1, Rusinek D1, Rusin A2, Kowal M1, Kowalska M1, Tyszkiewicz T1, Chekan M3, Krajewska J1, Czarniecka A4, Chmielik E3, Jarzab B1
1Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, Poland, 2Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Center for Translational Research and Molecular Biology of Cancer, Gliwice, Poland, 3Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Tumor Pathology, Gliwice, Poland, 4Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Oncology Surgery Clinic, Gliwice, Poland
OP49 IGF-I PROLIFERATIVE EFFECTS ARE INHIBITED BY TARGETING PKC IN HUMAN MEDULLARY THYROID CARCINOMA CELLS
Molè D1, Gagliano T1, Gentilin E1, Bondanelli M1, Tagliati F1, degli Uberti DUC1, Zatelli MC1
1University of Ferrara, Section of Endocrinology, Dept of Biomedical Sciences and Advanced Therapies, Ferrara, Italy
OP50 CAMP ANALOGS: A NEW PERSPECTIVE IN THE TREATMENT OF POORLY DIFFERENTIATED THYROID CANCER
Grassi ES1, de Filippis T2, Lucchi S2, Calebiro D2, Persani L1,2,3
1University of Milan, Medical Sciences, Milan, Italy, 2IRCCS Istituto Auxologico Italiano, Laboratory of Endocrine-Metabolic Research, Cusano Milanino, Italy, 3IRCCS Istituto Auxologico Italiano, Division of Endocrinology and Metabolic Diseases, Milan, Italy
OP51 PODOPLANIN AND PROX 1 IN DIFFERENTIATED THYROID TUMORS
Janik J1, Strzyżewska-Jówko I1, Hanusek K1, Bardadin K2, Czerwińska J2, Górnicka B3, Kiedrowski M4, Olszewski W4, Czarnocka B1
1Medical Center of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland, 2Medical Center of Postgraduate Education, Department of Pathology, Warsaw, Poland, 3Medical University of Warsaw, Department of Pathology, Warsaw, Poland, 4Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Pathology, Warsaw, Poland
OP52 FUNCTIONAL ANALYSIS OF MOLECULAR PROFILE OF CHILDHOOD/ADOLESCENTS RADIATION INDUCED THYROID CANCER
Handkiewicz-Juak D1, Swierniak M1, Rusinek D1, Oczko-Wojciechowska M1, Dom G2, Maenhaut C2, Unger K3, Detours V2, Bogdanova T4, Thomas G3, Kowalska M1, Chmielik E5, Jarzab M6, Swierniak A7, Jarzab B1
1Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland, 2Université Libre de Bruxelles, Institute of Interdisciplinary Research, Bruxelles, Belgium, 3Imperial College London Hammersmith Hospital, Human Cancer Studies Group, Division of Surgery and Cancer, London, United Kingdom, 4Institute of Endocrinology and Metabolism, Kiev, Ukraine, 5Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Tumor Pathology Department, Gliwice, Poland, 6Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Radiation Therapy Department, Gliwice, Poland, 7Silesian University of Technology, Gliwice, Poland
OP53 RET SOMATIC MUTATIONS ARE NOT AN EARLY EVENT IN THE TUMORAL TRANSFORMATION OF SPORADIC MEDULLARY THYROID CANCER
Romei C1, Cosci B1, Ugolini C2, Bottici V1, Molinaro E1, Agate L1, Tacito A1, Basolo F2, Miccoli P2, Vitti P1, Pinchera A1, Elisei R1
1University of Pisa, Department of Endocrinology, Pisa, Italy, 2University of Pisa, Department of Surgery, Pisa, Italy
OP54 MEK INHIBITION REDUCES THE DEDIFFERENTIATION INDUCED BY EPIDERMAL GROWTH FACTOR, RESTORING THE EXPRESSION OF AND THE IODIDE TRANSPORT MEDIATED BY THE SODIUM IODIDE SYMPORTER (NIS) IN CULTURED THYROCYTES
Ingeson C1, Carlsson T1, Nilsson M1
1University of Gothenburg, Sahlgrenska Academy, Institute of Biomedicine, Gothenburg, Sweden
10.00-10.30
Coffee Break
10.30-12.00 Minor Hall
Symposium 5 Basic: Thyroid hormone and metabolism
Chair: Ana Aranda (Madrid, Spain); Janusz Nauman (Warsaw, Poland)
Local control of thyroid hormone action and energy homeostasis
Antonio Bianco (Miami, USA)
Control of thermogenesis and lipid metabolism by T3 and its analogs. Induction of uncoupling protein 1 in white fat
Maria Jesus Obregon (Madrid, Spain)
The effects of thyroid hormone on muscle metabolism via regulation of uncoupling protein 3
Maria Moreno (Benevento, Italy)
10.30-12.00 Main Hall (Aula Duza)
Symposium 6 Clinical: Monitoring of thyroid cancer
Chair: Maria Alevizaki (Athens, Greece); Alicja Hubalewska-Dydejczyk (Krakow, Poland)
PET scanning (including FDG, I-124, FDOPA) in thyroid carcinoma
Sophie Leboulleux (Villejuif, France)
Use of sensitive Tg assays in the follow-up of DTC
Rossella Elisei (Pisa, Italy)
Follow-up of MTC including imaging and biochemical markers
Barbara Jarzab (Gliwice, Poland)
12.00-13.00 Poster Exhibition Hall
Lunch and Poster Discussions 3 (see separate PDF for further information)
Thyroid Cancer (clinical) 7: Posters PO212-PO222 / Chair: Clive Harmer London, UK)
Thyroid Cancer (clinical) 8: Posters PO223-PO232 / Chair: Nese Colak Ozbey (Istanbul, Turkey)
Thyroid Cancer (basic/translational) 3: Posters PO233-PO241 / Chair: Christine Spitzweg (Munich, Germany)
Graves’ Hyperthyroidism 3: Posters PO242-PO252 / Chair: Stig Andersson (Aalborg, Denmark)
Thyroid Hormone & Bone: Posters PO253-PO261 / Chair: Peter Smyth (Dublin, Ireland)
Hypothyroidism 2: Posters PO262-PO275 / Chair: Agathokles Tsatsoulis (Joannina, Greece)
Goiter/Nodules 2: Posters PO276-PO289 / Chair: Hans Graf (Merces, Brazil)
Genetics of Thyroid Disease: Posters PO290-PO297 / Chair: Thomas Brix (Odense, Denmark)
Thyroid Cell Biology and Thyroid Hormone Action: PO298-PO309 / Chair: Mikael Nilsson (Göteborg, Sweden)
13.00-14.00 Main Hall (Aula Duza)
Lunch Symposium Bayer Healthcare
CHALLENGES AND OPPORTUNITIES IN THE TREATMENT OF PATIENTS WITH RAI-REFRACTORY DIFFERENTIATED THYROID CANCER (DTC)
13.00 Welcome and Introduction
Alicja Hubalewska-Dydejczyk (Krakow, Poland)
13.05 Challenges in Defining RAI-Refractory DTC
and Review of the Current Treatment Algorithm
Martin Schlumberger (Villejuif, France)
13.20 Targeted Therapies in RAI-Refractory DTC:
Rationale for Use and Clinical Development
Marcia Brose (Philadelphia, United States)
13.40 Multi-Disciplinary Perspectives in the Treatment of
RAI-Refractory DTC: A Case-Study Approach
Johannes Smit (Leiden, Netherlands)
Marcia Brose
Alicja Hubalewska-Dydejczyk,
Martin Schlumberger
14.00 Summary and Conclusion
Marcia Brose
14.00-14.45
Meet the Expert
MTE 9 (B) Senate Hall: Signalling pathways in the thyroid
Davide Calebiro (Würzburg, Germany)
MTE 10 (C) Lecture Hall: Novel treatment modalities for thyroid cancer
Jan Smit (Leiden, The Netherlands)
MTE 11 (C) Minor Hall: Thyroid and Pregnancy: results of a survey among ETA members
Kris Poppe (Brussels, Belgium)
14.45-15.00
Coffee Break
15.00-17.00 Main Hall (Aula Duza)
Oral presentations 8: Hypothyroidism, Goiter and Nodules (OP55-OP62)
Chair: Laszlo Hegedus (Odense, Denmark); Jerzy Sowinski (Poznan, Poland)
OP55 THYROID HORMONES, ANDROGEN RECEPTORS AND TESTICULAR DEVELOPMENT
Rijntjes E1, Snaas S2, Swarts HJM2, Keijer J2, Teerds KJ2
1Charité Universitätsmedizin Berlin, Institute for Experimental Endocrinology, Berlin, Germany, 2Wageningen University, Department of Animal Sciences, Wageningen, Netherlands
OP56 MICRORNAS EXPRESSION FOR DIFFERENTIATION OF BENIGN AND MALIGNANT THYROID NODULES STARTING FROM CELLS OF FINE NEEDLE ASPIRATION
Ferrarini E1, Agretti P1, Candelieri A2, Rago T1, Conforti D2, Musmanno R2, Miccoli P1, Di Coscio G1, Pinchera A1, Vitti P1, Tonacchera M1
1Università di Pisa, Pisa, Italy, 2Università della Calabria, Cosenza, Italy
OP57 DIAGNOSTIC VALUE OF ULTRASONOGRAPHY TO DISTINGUISH BETWEEN BENIGN AND MALIGNANT THYROID NODULES. A PROSPECTIVE STUDY WITH 13902 PATIENTS
Solymosi T1
1Bugat Hospital, Thyroid Outpatient Department, Gyongyos, Hungary
OP58 CURRENT PRACTICE TO DIAGNOSE AND TREAT THYROID NODULES IN GERMANY
Bormann R1, Adler J-B2, Scholz M3, Paschke R1
1Universität Leipzig, Klinik für Endokrinologie und Nephrologie, Leipzig, Germany, 2Wissenschaftliches Institut der AOK (WIdO), Forschungsbereich Integrierte Analysen, Berlin, Germany, 3Universität Leipzig, Institut für medizinische Informatik, Statistik und Epidemiologie, Leipzig, Germany
OP59 INTRODUCTION OF THE DANISH IODINE FORTIFICATION PROGRAM: IMPACT ON DRUG AND TREATMENT COSTS
Cerqueria C1, Knudsen N2, Ovesen L3, Laurberg P4, Perrild H2, Rasmussen LB5, Jørgensen T1,6
1Research Centre for Prevention and Health, Glostrup, Denmark, 2Bispebjerg Hospital, Department of Endocrinology and Gastroenterology, Copenhagen, Denmark, 3Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark, 4Aalborg Hospital, Aarhus University Hospital, Department of Endocrinology, Aalborg, Denmark, 5National Food Institute, Technical University of Denmark, Department of Nutrition, Søborg, Denmark, 6University of Copenhagen, Faculty oof Health Sciences, Copenhagen, Denmark
OP60 IODINE DEFICIENCY DISORDERS IN THE SO-CALLED HIMALAYAN GOITRE BELT: A TWO DECADE PROFILE
Chandola-Saklani A1, Farswan A1, Bamola VD1, Lakhera PC2, Kathait A2, Kumar D2
1Apeejay Stya University, Centre for Biosciences and Clinical Research, Gurgaon, India, 2HNB Garhwal Central University, Department of Biotechnology, Srinagar Garhwal, India
OP61 LEVOTHYROXINE MONOTHERAPY CANNOT GUARANTEE EUTHYROIDISM IN ALL ATHYREOTIC PATIENTS
Latina A1, Frasca F1, Vigneri R1, Gullo D1
1Garibaldi Hospital, University of Catania, Endocrinology Division, Dept. of Clinical and Molecular Biomedicine, Catania, Italy
OP62 NEWBORN SEX RATIO IS ASSOCIATED WITH MATERNAL TSH
Miñambres I1, Ovejero D2, García-Patterson A2, Adelantado JM2, Corcoy R2
1Hospital de la Santa Creu i Sant Pau, Endocrinology, Barcelona, Spain, 2Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
15.00‐17.00 Minor Hall
Oral presentations 9: Thyroid Cell Biology and Genetics (OP63-OP70)
Chair: Paolo Beck-Peccoz (Milano, Italy); Anhelli Syrenicz (Szczecin, Poland)
OP63 TSH COMPENSATES THYROID SPECIFIC IGFI RECEPTOR KNOCKOUT AND CAUSES PAPILLARY THYROID TUMOURS
Müller K1, Führer D1, Mittag J2, Klöting N1, Blüher M1, Weiss RE3, Many M-C4, Schmid KW5, Krohn K6
1University of Leipzig, Department of Internal Medicine, Division of Endocrinology, Diabetologia and Nephrology, Leipzig, Germany, 2Karolinska Institute, Department of Cell and Molecular Biology, Stockholm, Sweden, 3The University of Chicago, Department of Medicine, Section of Adult and Pediatric Endocrinology, Diabetes and Metabolism, Chicago, United States, 4Universite catholique de Louvain, Medical School, Brussels, Belgium, 5University of Duisburg-Essen, Institute of Pathology and Neuropathology, Essen, Germany, 6University of Leipzig, IZKF - Core Unit DNA Technologies, Leipzig, Germany
OP64 MICRORNAS REGULATE THYROID CELL PROLIFERATION INDUCED BY TSH AND THYROGLOBULIN
Akama T1, Kawashima A1, Wu H1, Tanigawa K1, Sue M1, Yoshihara A1, Ishido Y1, Suzuki K1
1National Institute of Infectious Diseases, Higashimurayama-shi, Japan
OP65 EXPRESSION, MATURATION AND TURNOVER STUDIES OF PENDRIN VARIANTS WITH NORMAL OR SLIGHTLY REDUCED FUNCTION
Vezzoli V1, Cirello V2, Bazzini C3, Muzza M2, Castorina P4, Maffini A4, Beck-Peccoz P2,4, Persani L1,2, Meyer G3, Fugazzola L4
1IRCCS Istituto Auxologico Italiano, Research Laboratory of Endocrinology and Metabolic Disorders, Milan, Italy, 2University of Milan, Dept of Medical Sciences, Milan, Italy, 3University of Milan, Laboratory of Molecular and Transport Physiology, Department of Biomolecular Sciences and Biotechnology, Milan, Italy, 4Fondazione IRCCS Ca' Granda, Endocrine and Genetic Units, Milan, Italy
OP66 A “CUSTOMIZED” CGH-ARRAY THYROARRAY® IDENTIFIES GENETIC DEFECTS IN CONGENITAL HYPOTHYROIDISM NOT DETECTABLE BY PCR AND SEQUENCING
Moya CM1, Vallespín E2, Szkudlarek A1, Persani L3, Martín-Pena M4, Fugazzola L5, Polak M4, Visser T6, Lapunzina P2, Nevado J2, Moreno JC1
1INGEMM- Institute for Medical and Molecular Genetics. La Paz University Hospital, Thyroid Molecular Laboratory, Madrid, Spain, 2INGEMM- Institute for Medical and Molecular Genetics. La Paz University Hospital, Structural and Functional Genomics Laboratory, Madrid, Spain, 3IRCCS Istituto Auxologico Italiano, Endocrinology and Metabolic Diseases, Milan, Italy, 4Necker-Enfants Malades Hospital, Pediatric Endocrinology, Paris, France, 5Fondazione IRCCS Policlinico, Endocrinology and Diabetology Unit, Milan, Italy, 6Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands
OP67 FUNCTIONAL CHARACTERIZATION OF TSHR HINGE REGION RESIDUES IDENTIFIED FURTHER TEN TSH INTERACTION SITES OUTSIDE OF THE LRR
Mueller S1, Szkudlinski MW2, Schaarschmidt J1, Günther R3, Paschke R1, Jaeschke H1
1University of Leipzig, Department of Internal Medicine, Neurology and Dermatology, Leipzig, Germany, 2Trophogen Inc., Rockville, United States, 3University of Leipzig, Institute of Biochemistry, Leipzig, Germany
OP68 BIALLELIC DUOX2 VARIANTS APPEAR INVARIABLY ASSOCIATED WITH PERMANENT CONGENITAL HYPOTHYROIDISM
Muzza M1, Zamproni I2, Persani L3, Cortinovis F2, Vigone MC2, Rabbiosi S2, Beccaria L4, Visser TJ5, Moreno J6, Weber G2
1Fondazione IRCCS Cà Granda, Endocrinology Unit, Milan, Italy, 2San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Pediatrics, Milan, Italy, 3University of Milan, and Istituto Auxologico Italiano, Department of Medical Sciences, Milan, Italy, 4A. Manzoni Hospital, Pediatric Unit, Lecco, Italy, 5Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands, 6“La Paz” University Hospital, Thyroid Molecular Laboratory-INGEMM- Institute for Medical and Molecular Genetics, Madrid, Spain
OP69 SUBCELLULAR LOCALIZATION OF S6K1 AND S6K2 IS RELATED TO FUNCTIONAL ACTIVITY OF RAT THYROCYTES IN VITRO
Khoruzhenko A1, Cherednyk O1, Tykhonkova I1, Filonenko V1
1Institute of Molecular Biology and Genetics, Department of Cell Signaling, Kyiv, Ukraine
OP70 REGULATION OF H2O2 GENERATION BY THYROGLOBULIN IN FRTL-5
Yoshihara A1, Kawashima A1, Tanigawa K1, Akama T1, Wu H1, Sue M1, Ishido Y1, Hiroi N2, Yoshino G2, Suzuki K1
1Laboratory of Molecular Diagnostics, Leprosy Research Center, National Institute of Infectious Diseases, Tokyo, Japan, 2Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
17.15-18.45 Main Hall (Aula Duza)
General Assembly
20.00
Gala Dinner
